Dr. Florian Kirschenhofer Start-up Manager Max-Planck-Innovation GmbH Start-up Management as Technology Transfer within the Max-Planck- Society UN Conference, Geneva, 11th of April 2008
Max-Planck-Gesellschaft (Max-Planck-Society) Basic research organization in Germany 79 Max Planck Institutes (MPIs) 32 Life science section (BMS) 29 Chemical, physical, technical section (CPTS) 18 Social sciences and humanities (GSHS) Financing: 82% federal and state funds (50:50); + donations, membership fees, project funding; budget: 1,38 billion 12.400 employees + 10.900 Ph.D. students, post-docs, guest scientists etc. 2 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Max-Planck-Innovation GmbH (MI) founded in 1970 as "Garching Instrumente GmbH as technology transfers agency of the Max Planck Society (100% subsidiary) 1993 renamed in "Garching Innovation GmbH, Technologien aus der Max-Planck-Gesellschaft 2006 renamed in Max Planck Innovation GmbH MI informs the Max-Planck-Institutes and their scientists on all aspects of technology transfer MI gives advice with respect to patentability and economic potential of inventions assignment of external patent attorneys world-wide search for licensees option- and license agreements start-up consultancy and portfolio-management 3 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
The People at MI 4 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Commercialization of technologies within the Max-Planck-Society Technologies Profit Downpayment Royalties etc. License Support License Shares Downpayment Royalties etc. Licenses to existing companies Support of Start-Ups 5 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Process to identify Opportunities =>! MPI Scientist Invention!!!! Invention Disclosure Form to MI First evaluation from License Manager (LM) LM contacts Start-up Manager (SM) Inventor contacts SM MI builds interdisciplinary team (LM+SM) First Evaluation of technology Support: Information events at Max- Planck-Insituts (MPI) Meeting with MPI directors Web-page, flyers, posters Contact for federal and state programs But: No active Technology scouting-process 6 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Coaching of start-ups Pre-Seed Foundation and Financing Later Stage Evaluation of the founding idea and the first company concept Consulting on patent matters Support of the business and financial planning/strategy Negotiation of investment- and shareholder agreements for MPG Support at negotiation with Investors Negotiation of license agreements Long term coaching by board memberships Portfolio management Follow up financing Exit strategy Contacting financial partners (i.e. VC) Search for suitable development funds Support to build up network (in all stages of the firm) 7 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Some possible public programs Pre-Seed Foundation and Financing Later Stage Innovation meets management An Initiative of Lead Discovery Center EEF follow up program Other public banks (i.e. Bayernkapital) Other public banks (i.e. Bayernkapital) 8 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Facts and Figures Income (Licenses and Share Sales) (Mio EUR) 9 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Facts and Figures Cost-Benefit Analysis (Mio EUR) 10 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Facts and Figures Spin-Offs 11 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Start-ups since 1990 82 start-ups since 1990 45 VC financings (37 private + 8 corporate deals) 50 successful projects coached by Max Planck Innovation 7 companies listed on the stock-exchange, 12 M&A-Deals 2.220 employees 18 projects in different stages currently supported 24 portfolio companies of Max-Planck-Society, thereof 3 exits und 2 partial exits 5 write-offs (thereof 3 successful re-starts) 3 direct investment of Max-Planck-Innovation GmbH 12 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Examples for successful start-ups Sugen ( Pharmacia / Pfizer) Evotec ( Oxford Assymetry Ltd.) TF Instruments GmbH PlantTec Biotechnology ( Bayer Crop Science) GPC Biotech Epigenomics DeveloGen Artemis Pharmaceuticals ( Exelixis, now Taconic Farms, Inc.) Ingenium Pharmaceuticals Metanomics Proteros Biostructure Protagen AG Cenix BioScience GmbH Capsulution NanoScience AG Scienion AG U3 Pharma AG Alnylam Pharmaceuticals, Inc. ( Ribopharma AG) MenloSystems GmbH JADO Technologies Affectis Pharmaceuticals Inc. ECMTEC GmbH SuppreMol GmbH KINAXO Biotechnologies GmbH 13 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008
Thank you Florian Kirschenhofer Max-Planck-Innovation GmbH Marstallstraße 8 80539 München Telefon +49 (89) 29 09 19-0 Telefax +49 (89) 29 09 19-99 kirschenhofer@max-planck-innovation.de www.max-planck-innovation.de 14 Dr. Florian Kirschenhofer UN, Geneva, 11th of April 2008